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RESEARCH INVOLVING BIOSPECIMENS:  
INCORPORATING A TRUST MODEL INTO THE COMMON RULE 
 
Kristen M. Burt 
 
INTRODUCTION 
Debate about research involving existing biospecimens has been highly visible in recent 
years due in part to litigation1 and publication of books such as The Immortal Life of Henrietta 
Lacks by Rebecca Skloot.2  Biospecimens by their nature may be obtained, stored sometimes for 
many years, and used in subsequent research activities. Biospecimens include blood, tissue, cells, 
and other human materials which contain genetic information.3 As technology advances, 
biospecimens are seen as valuable resources that can be used in research to discover new ways to 
diagnosis, treat, and prevent disease.4 However, this use can raise issues of informed consent as 
highlighted by the litigation filed by individuals whose biospecimens or those of their child had 
been used for research without permission.     
                                                   
1 See e.g., Havasupai v. Ariz. State Univ., 220 Ariz. 214 (2009), Wash. Univ. v. Catalona, 490 F.3d 667, 670 (2007),  Moore v. 
Regents Univ.  Cal., 51 Cal.3d 120, 125-26 (1990), Greenberg v. Miami Children’s Hosp. Research Inst. 264 F. Supp. 2d 
1064, 1066-67 (2003). 
2 REBECCA SKLOOT, THE IMMORTAL LIFE OF HENRIETTA LACKS (Crown 2010) (2010) (focuses on the story behind 
the HeLa cells, a cell line used in many research studies and that has contributed to a number of scientific advancements and 
raised issues such as informed consent). 
3 http://www.cancer.gov/dictionary?expand=B (April 1, 2012). 
4 http://biospecimens.cancer.gov/relatedinitiatives/default.asp (April 1, 2012). 
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There is a federal regulation, the Basic HHS Policy for Protection of Human Research 
Subjects codified by the U.S. Department of Health and Human Services Under 45 C.F.R. 46 
Subpart A. Multiple federal agencies have adopted and codified 45 C.F.R. 46 Subpart A, causing 
the regulation to be referred to as the “Common Rule” because it is common across multiple 
federal agencies.5 This regulation applies to human subject research conducted or supported by 
federal agencies, requiring review and approval of an Institutional Review Board (IRB) with 
certain exemptions. However, the current regulation does not adequately address research 
involving existing biospecimens. Certain provisions of this regulation can exclude and exempt 
research projects that involve the use of existing biospecimens when the provision is met. This 
means that the issues of informed consent raised by individuals whose biospecimens used in 
research are not adequately addressed.  
To address issues raised by these examples and others, an Advanced Notice of Proposed 
Rulemaking (ANPR) was published in the Federal Register on July 26, 2011 suggesting 
substantial changes to the human research protection regulations.6 While the ANPR does address 
some of the exclusions and exemptions that raised concern, this paper will argue that the changes 
proposed in the ANPR do not fully address concerns that arise when research is conducted on 
existing biospecimens. Instead, a model based on a trust structure should be incorporated into the 
human research protection regulations to better address these issues and protect the parties’ 
interests typically involved in secondary research involving biospecimens. The model for a trust 
has been proposed for research involving biospecimens to address valuable commercial research 
                                                   
5 http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html (May 8, 2012). 
6 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512 (advanced notice of proposed rulemaking July 26, 2011).  
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where revenue may be generated by the research.7 The trust model has also been used in the 
context of when newborn blood spots are collected for clinical purposes and to permit research 
use on such blood spots.8 The trust model should be incorporated into the Common Rule.  
A trust is a property model in which a settlor places property into the trust for the benefit 
of a beneficiary and is managed by a trustee.9 The terms of the trust define how the property is to 
be used.10 The trust model distributes responsibility and management of the property and 
provides checks and balances to assure that the property is used as the settlor defined in the terms 
of the trust. Proposing revisions to the human research protection regulation based on a trust 
structure balances the needs of the three parties involved in research with biospecimens: the 
individual providing the biospecimen, the researcher(s), and the institution that employs the 
researcher(s). This paper will argue that the trust model provides checks and balances needed for 
research involving biospecimens and will propose informed consent requirements as the terms of 
the trust presented to the individual providing the biospecimen as the settlor and argue for 
additional responsibilities as duties for the institution as the trustee and for the investigator as the 
beneficiary. The current structure of the Common Rule is already somewhat structured to 
facilitate a trust model because of the parties involved in research and informed consent 
requirements; however, applying the trust model in the paper highlights and divides the 
                                                   
7 See Joyce Boyle, To Pay or Not to Pay, That is the Question: Finding an Intermediary Solution Along the Moore Spectrum, 7 
MICH. ST. J. MED. & L. 55 (2002) (establish federal commission where tissue is placed in trust and provide compensation), 
William Hanes, Rejection of the Need for Informed Consent in Prostate Tissue Sample Research, 14 Cardozo J. L. & Gender 
401 (2008), Martin Harvey, Towards a Public Human Tissue Trust, 59 CASE W. RES. L. REV. 1171 (2009) (establishment of 
public tissue trust for ownership).  
8 Denise Chrysler et. Al.,  The Michigan Biotrust for Health: Using Dried Bloodspots for Research to Benefit the Community 
While Respecting the Individual, 39 J. L. MED. & ETHICS 98 (2001) (Michigan Newborn Bloodspot Model (describes 
establishment of Michigan Biotrust based on a charitable trust model based on qualified ownership of the sample). 
9 RESTATEMENT (THIRD) OF TRUSTS § 2 (2003). 
10 Id. at § 4. 
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responsibilities of each party to indicate what changes should be incorporated into the Common 
Rule when it is revised. 
 This paper will argue that the current regulations and ANPR do not adequately address 
concerns raised by individual whose biospecimens are used in research and proposes a model 
based on a property trust structure to better address these issues.  Part I will set forth the 
background of the current and proposed regulatory framework as it applies to research involving 
existing biospecimens and will introduce the proposal for a model based on a trust structure. In 
Part II, the current regulation and ANPR proposals will be evaluated and the trust model will be 
proposed for prospective collection of biospecimens. Part III will then apply the current, advance 
notice, and trust proposal to research using existing biospecimens. Part IV will evaluate issues 
that arise after research is approved, such as withdrawal and sharing of biospecimens, and argue 
that the trust model provides a better structure to address these areas. Overall, this paper will 
suggest that a trust model and specific changes to informed consent and additional review 
considerations based on this model are needed to address concerns raised when research is 
conducted on biospecimens.  
I.  BACKGROUND 
This section will provide background on the current human research protection 
regulation, the ANPR proposals, and will introduce the proposal for a model based on a trust 
structure to be incorporated into the human research protection regulation.  
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A.  Current Common Rule 
The Common Rule applies to human subject research and is applicable to an institution 
when a federal agency supports the research project.11 An institution may voluntarily choose to 
extend the oversight of the federal government by “checking the box” on the Federal Wide 
Assurance provided to the U.S. Office for Human Research Protections to extend the regulation 
to all human subject research conducted at the institution, regardless of funding source.12 While 
the ANPR proposes to extend the applicability of the Common Rule to any domestic institution 
that receives federal funding,13 an evaluation of this change is beyond the scope of this paper and 
as a result, this paper assumes the applicability of the Common Rule. Even if the Common Rule 
is not applicable to the institution, incorporating this paper’s proposals into the Common Rule 
would provide a baseline or standard for the review of research involving biospecimens. 
Institutions will often apply the Common Rule to research regardless of funding source, even if 
the box is not checked. 
The Common Rule requires review by an Institutional Review Board unless the research 
qualifies for an exemption. Approval criteria such as evaluation of risks and benefits, the 
informed consent process, and selection of subjects are specified and must be met in order for the 
IRB to approve the research.  These requirements would also apply to research involving 
biospecimens, although provisions of the regulation exclude certain uses of biospecimens from 
IRB review, including informed consent requirements.14  
                                                   
11 45 C.F.R. § 46.101(a) (2011). 
12 45 C.F.R. § 46.103(a) (2011). 
13 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44528 (advanced notice of proposed rulemaking July 26, 2011). 
14 45 C.F.R. § 46.101 (2011). 
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Research involving existing biospecimens can be excluded from applicability of the 
Common Rule through several provisions.15 First, the definition of human subject limits who a 
human subject is to identifiable private information.16 Currently, a biospecimen is not considered 
identifiable in and of themselves.17 Therefore, unless a name or code is associated with the 
biospecimen, research can be conducted using the biospecimen without falling under the 
Common Rule.18 Second, even if the biospecimen is considered a human subject, the research 
may qualify for an exemption and be exempt from the Common Rule requirements.19 Third, even 
if the research comes under the Common Rule and is not exempt, the IRB may grant a waiver of 
consent if the research meets certain criteria.20 Under each of these scenarios, informed consent 
from the individual to use their biospecimen in the research would not be required. Each of these 
provisions will be applied in Part II and III to highlight deficiencies in the regulation.  
B.  Advanced Notice of Proposed Rulemaking 
 The changes suggested in the ANPR are the most significant since proposed rules were 
published in 197921 and broadly encompasses provisions for exemptions, multi-site research, 
data security, and informed consent.22 Some of the changes proposed attempt to address 
deficiencies related to research involving existing biospecimens.23 The ANPR proposes that 
because of the identifiable nature of biospecimens, all research involving biospecimens, whether 
                                                   
15 45 C.F.R. § 46.101 (2011). 
16 45 C.F.R. § 46.102(f) (2011). 
17 Id. 
18 45 C.F.R. § 46.101 (2011). 
19 45 C.F.R. § 46.101(b)(4) (2011). 
20 45 C.F.R. § 46.116(d) (2011). 
21 http://www.hhs.gov/ohrp/humansubjects/index.html (OHRP explanation of the ANPR) (May 8. 2012).  
22 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512 (advanced notice of proposed rulemaking July 26, 2011).  
23 Id. at 44524.  
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collected, stored, or analyzed, would be considered identifiable information24 in contrast to the 
current definition of a human subject which excludes biospecimens cannot be readily linked to a 
name or code. The ANPR proposes to expand the current exempt category (4) that is limited to 
existing biospecimens to all secondary research use of identifiable data and biospecimens that 
have been collected for purposes other than the currently proposed research25 but require consent 
for exempt research.26  Also, rather than IRB review of the exemption, the researcher would 
instead file a registration with the IRB but are allowed to proceed without IRB review.27 Each of 
these proposals will be critiqued and arguments will be made in Part II, III, and IV for additional 
changes based on a trust model.  
C.  Trust Model 
This paper will argue that the current and proposed requirements should be further modified 
to address issues related to research involving biospecimens. The model proposed is based on a 
property trust structure. The model for a trust has been proposed to address biospecimens 
commercial interests28 and in the context of newborn blood spots.29 A structure modeled on a 
trust could also be effective in a broader context for research involving biospecimens and should 
be incorporated into the Common Rule as part of its revisions.  
A trust is created when there is an intention to form a relationship where property is 
passed to a person who then holds title to the property and has a duty to manage that property for 
                                                   
24 Id. at 44525. 
25 Id. at 44519. 
26 Id. 
27 Id. 
28 See, e.g., Boyle, supra note 7. The author discusses the establishment of a federal commission where tissue is placed in trust 
and compensation is provided. 
29 Chrysler, supra note 8 (describes establishment of Michigan Biotrust based on a charitable trust model based on qualified 
ownership of the sample). 
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the benefit of another.30 A settlor creates the trust by providing the property.31 The property held 
by the trust is the property that the settlor provided.32 The trustee is the person who manages the 
property and may be more than one person.33 The beneficiary is the person who receives the 
benefit of the property held in the trust and there may be more than one person also.34 A person 
may be a corporate or other entity.35 The terms of the trust define the use of the property and 
defines the intention of the settlor.36 The terms of the trust may be written or may be implied.37 A 
trust may be created by the inter vivos transfer of property to a trustee for a beneficiary.38 The 
terms of the trust is created for the benefit of the beneficiary.39 Any type of property may be 
placed in a trust.40 The beneficiary needs to be identified or a definite class defined; the 
beneficiary must be capable of being identified by the description of the terms of use.41 The 
intention of the settlor defines the beneficiaries’ interest in the trust.42The settlor may revoke or 
modify the trust based on the intention expressed in the terms of the trust.43 The trustee is 
responsible for carrying out the terms of the trust as defined by the settlor.44 
Research involving biospecimens typically involves three parties: the human subject, the 
investigator, and the institution. The human subject is the individual who is actually providing 
                                                   
30 RESTATEMENT (THIRD) OF TRUSTS § 2 (2003). 
31 Id. at § 3. 
32 Id. 
33 Id. 
34 Id. 
35 Id.  
36 Id. at § 4. 
37 Id. 
38 Id. at § 10. 
39 Id, at § 27. 
40 Id. at § 40. 
41 Id. at § 44. 
42 Id. at § 49. 
43 Id. at § 63. 
44 Id. at § 70. 
Kristen	  M.	  Burt	   Research	  Involving	  Biospecimens	   9	  
 
the biospecimen or whose existing biospecimen is being used in the research study. The 
investigator is the individual who has is actually conducting the research. The institution is the 
entity that employees the investigator and may include hospitals, universities, etc. A framework 
modeled on a trust structure would appropriately balance the interests of human subjects, 
investigators, and institutions. The human subject would be the “settlor,” providing the 
“property,” i.e. the biospecimen, to the trust. The informed consent document would provide the 
written agreement regarding the use of the biospecimen and would define the scope of usage. 
The institution would be the “trustee,” providing oversight regarding the use of the biospecimen. 
The investigator would be the “beneficiary,” conducting research on the biospecimen. While this 
paper references the institution as part of the trust model, the responsibilities assigned to the 
institution may be delegated by the institution to the IRB. The framework for the overall trust 
structure will be developed through this paper and arguments will be made for why this model is 
more appropriate than the current and proposed requirements. 
D.  Phases of Biospecimen Research 
This paper divides research involving biospecimens into three distinct phases of the 
research process. Part II of the paper encompasses the first phase of research involving 
biospecimens: the prospection collection of the biospecimen. The prospective collection of the 
biospecimen means the actual taking of the biospecimen from an individual, which may be in the 
form of blood, tissue, saliva, hair, etc. This prospective collection involves the entry of the 
biospecimen (the property) into the research (trust) based on the informed consent (terms of the 
trust) reviewed by the institution (trustee) and presented to the human subject (settlor) by the 
researcher (beneficiary). For example, the biospecimen may be obtained in a research project for 
the express purpose for the research or it may be obtained as part of clinical care (e.g. surgery 
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removal of tumor) where the individual provides consent that the biospecimen (or an extra 
biospecimen can be obtained during the research study) can be used in research.  
Part III of the paper will evaluate issues related to the second phase of research involving 
biospecimens: research involving existing biospecimens. Research on existing biospecimens 
means that the biospecimen has already been obtained, is being stored in a lab or facility, could 
have been obtained under any of the three prospective methods described, and a researcher wants 
to use the biospecimen for another research purpose. The researcher (beneficiary) will submit the 
research to the institution (trustee) who will review the use based on the informed consent (terms 
of the trust) originally provided by the human subject (settlor). 
Part IV of the paper will discuss issues related to the third stage of the research, 
withdrawal or sharing of the biospecimen once it has already been collected and is being used in 
prospective research, in research involving existing biospecimens, or both.   This section will 
provide additional considerations for withdrawal procedures that the institution (trustee) will 
coordinate and communicate to researchers (beneficiaries) based on the informed consent (terms 
of the trust). This section will also discuss considerations when the biospecimen will be shared 
by other researchers (additional beneficiaries) to assure that such sharing will meet the informed 
consent (terms of the trust). 
II. PROSPECTIVE BIOSPECIMEN RESEARCH 
The next section will discuss the prospective collection of the biospecimen for research 
purposes as the entry into the trust model. The investigator would prospectively submit an 
application to the institution’s IRB describing the proposed research for review and approval of 
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the research project prior to initiating the research, as is the current practice.45  Part A will 
discuss the informed consent document presented to the human subject that defines the research 
scope as the terms of the trust. This section argues that the Common Rule and the ANPR do not 
adequately address informed consent issues raised in litigation and that additional specific 
standards to define this informed consent process should be incorporated into the Common Rule. 
Part B will discuss provisions that are currently not included in the Common Rule or the ANPR 
and should be to define the responsibilities of the investigator and institution. 
A.  Informed Consent Document 
The informed consent document would be considered the “terms of the trust” and would 
define the boundaries of how biospecimens could be used in current and future research. The 
institution, as the trustee, would prospectively review and approve the informed consent 
document, as is the current practice. The human subject, as the settlor, would agree to the terms 
of the informed consent presented by the researcher as the beneficiary. As the trustee, the 
institution would review the content of the informed consent document to assure that future 
research uses on existing biospecimens is fully disclosed to the human subject.  
How the informed consent is written is especially important because a court may find that 
conducting research outside of the scope of the original use or consent may constitute a cause of 
action.46 In 1963, an anthropology professor from Arizona State University began collaborating 
with the Havasupai tribe, located in the Supai Village at the bottom of the Grand Canyon.47 The 
anthropology professor was approached by a member of the tribe in 1989 to study diabetes.48 
                                                   
45 45 C.F.R. § 46.109 (2011) (applicable to expedited or full board review procedure). 
46 Havasupai v. Ariz. State Univ., 220 Ariz. 214 (2009). 
47 Id. at 217. 
48 Id. at 217. 
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The anthropology professor then approached a genetics professor at ASU, to work on a diabetes 
project.49 The genetic professor indicated an interest to also study schizophrenia, but the 
anthropology professor indicated that the tribe would likely not be interested in a schizophrenia 
study.50 The diabetes research was conducted between 1990 – 1992 with 200 Havasupai tribe 
members participating in the study and providing informed consent for participation on the 
diabetes research.51 In 2002, the anthropology professor learned that the blood draws and genetic 
information obtained for the diabetes study was used by the genetics professor and others in 
research projects on schizophrenia, evolutionary genetics, inbreeding, and migration of human 
populations from Asia to Native America.52    
 The Havasupai tribe filed suit and while the superior court initially granted summary 
judgment to ASU, the court of appeals reversed the superior court’s decision.53  Part of the 
determination made by the court was whether there was sufficient detail describing the alleged 
wrongdoing to contain facts supporting the monetary claim of 50 million.54 The court noted that 
the notice provided details asserting that the blood was obtained for a limited use and the 
additional tests performed were without informed consent and distributed to parties outside ASU, 
a fact not disclosed in the consent.55 The Havasupai alleged that the additional tests performed 
without consent violated the privacy of the individual tribe members and the cultural and 
religious privacy of the Havasupai tribe.56 The court cited several cases that had held the 
                                                   
49 Id. at 217.  
50 Id. at  217-18. 
51 Id. at 218. 
52 Id.  
53 Id. at 232. 
54 Id. at 226. 
55 Id. 
56 Id. 
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performance of additional unauthorized tests on biospecimens may be sufficient to state a claim 
for relief upon violation of privacy and is subjective.57  
The informed consent used in the research involving the Havasupai tribe did not describe 
the possibility of future research involving schizophrenia and other topics or provide an 
opportunity to consent.58 However, this use likely did not violate the Common Rule. While the 
Common Rule requires basic elements of informed consent be provided to subjects prior to being 
involved in a research study59 and additional elements when applicable, this provision is not 
applicable to research exempt from the Common Rule.60  
The advance notice proposes to require written general consent for exempt research.61 
This means that the individual participating in the research could consent to the current research 
project and for all future research uses.62 For example, if the Havasupai tribe members who 
participated in the research agreed to participate in the diabetes research but did not permit 
general research use, the biospecimens could not have been used for the other research studies. 
Providing permission for general research has been argued for in the past63 and would appear to 
address the concerns raised by the litigation involving the Havasupai tribe. It would also address 
the argument that individuals want to provide permission for use of their biospecimen in 
research, but not necessarily for every use.64 The advance notice proposes a brief general consent 
                                                   
57 Id. at 227. 
58 Id. at 226. 
59 45 C.F.R. § 46.116 (2011). 
60 45 C.F.R. § 46.101(b) (2011). 
61 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011). 
62 Id. at 44519. 
63 E.g., Henry T. Greely, Breaking the Stalemate: A Prospective Regulatory Framework for Unforeseen Research Uses of Human 
Tissue Samples and Health Information, 34 WAKE FOREST L . REV. 737 (1999). 
64 See, e.g., Leslie Wolf, Advancing Research on Stored Biological Materials: Reconciling Law, Ethics, and Practice, 11 MINN. 
J.L. SCI. & TECH. 99, 150-51 (2012), Greely, supra note 63. 
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that could be allowed for a set of encounters with an institution and provide subjects to say no to 
all future research.65 Certain categories of research could also be included to restrict certain 
research use.66  Subjects would be allowed to participate, even if they said no to future 
research.67  The proposal also suggests that a template could be used.68 Because this is an 
advanced notice, specific criteria have not yet been published. I would argue that the following 
criteria should be included in the proposed rule if the investigator is would like to obtain 
permission for future use. These requirements would be in addition to the current basic and 
additional elements of consent.69 The requirements could be added as an additional element of 
consent or added as a new section that encompasses consent elements for future research.  
1. Explanation of Future Research 
Currently an individual is provided specific information about a particular research study and 
agrees to participate in that study.70 General consent for all future research is not permitted under 
the Common Rule.71 The advance notice proposes to change this requirement and allow consent 
for future research.72 While there may be debate on whether a subject can truly provide informed 
consent to general research73, presenting them with the option and allowing them to decide 
balances the subject’s interest in deciding to participate and the investigator’s interest in 
conducting additional research in the future. If an investigator was required obtain consent from 
                                                   
65 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011) 
66 Id. at 44519-20. 
67 Id. at  44520. 
68 Id. at 44523.  
69 45 C.F.R. § 46.116 (2011). 
70 Id. 
71 Id.  (specific to the research study) 
72 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011) 
73 See, e.g., Wolf, supra note 64. 
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the subject for each study, it may be very difficult to locate the subject especially if names and 
identifiers were removed from the biospecimen.74 If the subject provides general consent, this 
difficulty is solved while still obtaining informed consent from the subject for the future 
research. However, the informed consent should fully explain what “future research” means and 
explain that this could include any type of research study (if there are no limitations). Individuals 
may not completely understand what future research truly means and to obtain full informed 
consent, complete disclosure should be provided.   
If the researcher has an intent to conduct another type of research project, even if the research 
proposal is not fully developed, such a project should be described in the future research section 
as an example of the future research. From the Havasupai court opinion, it appears that planning 
for the schizophrenia research commenced at the same time the diabetes research was begun, 
based on the preparation of a grant application.75 It is that type of scenario that should be fully 
disclosed to the subject. If there is likelihood that a certain type of research may be performed, 
that should also be disclosed to the subject in the future research explanation.   
2. Sharing of Biospecimen 
The informed consent should also disclose that as part of the future research, the biospecimen 
may be shared. Individuals may not realize that biospecimen may be shared with collaborators at 
other institutions, such as universities, hospitals, research institutes, etc.  Subjects may not realize 
that future research could mean future research by individuals other than the investigator or the 
institution where the investigator is employed. Because of this, an explanation should also be 
provided that the biospecimen may be stored in multiple locations. It has been proposed that if 
                                                   
74 See, e.g., Greely, supra note 63. 
75 Havasupai v. Ariz. State Univ., 220 Ariz. 214, 217-18 (2009). 
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such sharing is contemplated at the time of the research, it should be disclosed to the subject and 
if information about sharing is not provided, the biospecimen could not be shared.76 I would 
argue that information about sharing must be included even if such use is not contemplated; it 
should not be an optional statement that could or could not be included in the consent document. 
However, such sharing should be limited to the terms of the scope of the informed consent77 and 
should be specifically addressed in a Material Transfer Agreement which is discussed in further 
depth in Part IV. 
3. Confidentiality 
While confidentiality is included in the current basic elements of consent78, because of the 
unique characteristics of biospecimens, the informed consent should also explain the type of 
confidentiality that can be promised and limits on that confidentiality based on those 
characteristics. For example, if the biospecimen was shared, even if there is no name or code 
associated with it, the biospecimen would still be considered identifiable based on the DNA the 
specimen contains.79 In addition to describing limits of confidentiality based on the genetic 
information in the biospecimen, the informed consent should also explain whether names and 
codes will be maintained with the biospecimens.80 
4. Retention 
The informed consent should also explain how long the specimen will be kept81, explaining 
whether the specimen may be kept for many years or whether the specimen will be used up in the 
                                                   
76 Greely, supra note 63at 755. 
77 Id.  
78 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44525 (advanced notice of proposed rulemaking July 26, 2011). 
79 See, Wolf, supra note 64at 147-48(for general discussion of DNA identification). 
80 Greely, supra note 63at 755. 
81 Id. 
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research. Some have argued that storage should be limited in time or that indefinite storage must 
be approved by the IRB.82 However, if the subject has provided informed consent for the usage 
and it has been explained that the biospecimen may be stored for many years or indefinitely, 
there is no need for a limited retention period. Practically, tracking a limited retention period 
would be difficult, especially if the biospecimen is shared. If the subject provided consent for the 
storage period, there should not be a need for additional review and approval by the IRB. 
5. Categories 
The ANPR proposes providing categories of research that subjects could opt out of (e.g. 
categories that may be controversial).83 Subjects may want to participate in certain studies but 
not others.84  These categories could be pre-defined or written in by the subject.85 Very careful 
consideration and drafting should be given to what, if any categories of research, should be 
included in the Common Rule for opt out purposes. Specific definition of the categories should 
be provided (e.g. what is considered gene research). Difficulties may be presented if subjects 
were to write in categories. Practically, the tracking of such potentially diverse categories may be 
very difficult. In addition, guidance may need to be given to subjects who may not be aware of 
the types of potentially controversial studies that could be written in. While the underlying 
purpose of this criteria is understandable from a respect for persons perspective (i.e. 
biospecimens should not be included in research that would be objectionable), the 
operationalization of this requirement may prove problematic.  
                                                   
82 Id. 
83 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519-20 (advanced notice of proposed rulemaking July 26, 2011) 
84 See generally Julie A. Burger, What is Owed Participants in Biotechnology Research? 84 CHI. KENT L. REV. 55, 70-73 (2009). 
85 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44520 (advanced notice of proposed rulemaking July 26, 2011) 
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6. Commercialization 
Several cases indicate the need to directly address commercialization through an informed 
consent process.  
In 1976, John Moore was diagnosed with leukemia and went to UCLA where biospecimens 
were obtained by his physician.86 Additional biospecimens were obtained on subsequent visits 
and used to develop a cell line which was patented and highly valuable.87 John Moore was 
unaware that the biospecimens being obtained were being used in research and he filed suit.88 
The court held that the physician breached his fiduciary duty and held a lack of informed consent 
because the physician failed to disclose the extent of the research and economic actions.89 The 
physician failed to disclose facts material to the patient consent.90 Because of the physician-
patient relationship, the physician had a duty to disclose personal interests unrelated to the 
patient’s health, including research or economic interests, which may affect the patients’ health, 
including research or economic interests.91  
In another lawsuit, plaintiffs approached Dr. Matalon to study Canavan disease in 1987.92 
The plaintiffs approached other families of children that had Canavan disease to participate in the 
research and provide biospecimens.93 Dr. Matalon isolated the gene and unknown to the 
plaintiffs, a patent application was submitted for the genetic sequence.94 Because the subjects 
were not told about the patent and because of the consequences of the patent, such as restricting 
                                                   
86 Moore v. Regents Univ.  Cal., 51 Cal.3d 120, 125-26 (1990). 
87 Id. at 126 (1990). 
88 Id. at 126-27 (1990). 
89 Id. at 129 (1990). 
90 Id.  
91 Id.  
92 Greenberg v. Miami Children’s Hosp. Research Inst. 264 F. Supp. 2d 1064, 1066-67 (2003). 
93 Id. 
94 Id. at 1064. 
Kristen	  M.	  Burt	   Research	  Involving	  Biospecimens	   19	  
 
activity related to Canavan disease like prenatal testing and development of other treatments, the 
plaintiffs filed suit.95 The court determined that the medical consent law did not apply to medical 
researchers96, as distinguished from Moore97. The court declined to extend the duty of informed 
consent disclosure in research to include a researcher’s economic interest.98  
If the Common Rule was applied to both Moore and Greenberg, prospective review by the 
IRB99 and informed consent to use the biospecimens in the research100 would be required; 
however, the Common Rule would not necessarily require disclosure of the commercialization 
interest101. In the broader context of research involving biospecimens, the current elements of 
consent do not explicitly require disclosure of commercial interests and would not be addressed 
in any case if the research did not meet the definition of human subject or met exemption 
category 4.102  
While an existing conflict of interest may not exist at the time the research is proposed (e.g. 
the researcher may not be aware of a commercial opportunity or discovery), there may be 
likelihood for commercialization and a statement that explains that commercialization may occur 
should be required.103 The subject should be informed that they will not directly profit from 
providing the biospecimen.104 There has been debate about reimbursing subjects through various 
                                                   
95 Id. at 1067. 
96 Id. at 1069. 
97 Moore v. Regents Univ.  Cal., 51 Cal.3d 120, 129 (1990). 
98 Greenberg v. Miami Children’s Hosp. Research Inst. 264 F. Supp. 2d 1064, 1070 (2003). 
99 45 C.F.R. § 46.101 (2011) (requirement to undergo review under either expedited or full board review). 
100 45 C.F.R. § 46.116 (2011). 
101 Id. (basic and additional elements of consent may not require this disclosure). 
102 45 C.F.R. § 46.101(b)(4) (2011). 
103 Greely, supra note 63at755-56. 
104 2009 NIH Guidelines for Stem Cell Research, http://stemcells.nih.gov/policy/2009guidelines.htm (May 8, 2012) (similar type 
of statement required to be included in informed consent). 
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models when a research project is commercially successful.105 Whether subjects should be 
reimbursed for commercialization is beyond the scope of this paper, but the issue of 
commercialization should be addressed in the informed consent document. However, there will 
need to be a balance between explaining commercialization and assuring that such a statement is 
not exculpatory, which is not allowed under the current Common Rule.106,107 In addition, while 
the Moore and Greenberg court distinguished whether a disclosure was required based on 
fiduciary duty108,109, disclosure of commercialization information which is material to the 
decision making process should be included in the informed consent document even if a 
fiduciary relationship may not exist. 
7. Disclosure of Research Findings 
Some have argued that subjects should have the option to be informed of findings of the 
study.110 While findings should be provided if appropriate and if subjects wish to be re-
contacted, such determination must be made on a case by case basis. This provision is the in 
current additional elements of consent.111 Practically, there are limits on the ability to contact 
subjects if the research involves general consent. For example, the biospecimen may be used in a 
future research study and de-identified with no name or code. In such case, findings of that study 
could not be provided to the subject based on the lack of name identification. Such limits should 
be explained to the subject. 
                                                   
105 See, e.g., Charlotte Harrison, Neither Moore nor the Market: Alternative Models for Compensating Contributors of Human 
Tissue, 28 AM. J.L. & MED. 77, 93 (2002) (very valuable tissue, after original consent, when commercial value established), 
Greely, supra note 63at 758 (dedicating share to organizations represent subjects). 
106 45 C.F.R. § 46.116 (2011). 
107 http://stemcells.nih.gov/research/newcell_qa.htm#do (May 8, 2012) (U.S. N.I.H. provides a frequently asked question on use 
of exculpatory language for research involving embryonic stem cells).  
108 Moore v. Regents Univ.  Cal., 51 Cal.3d 120, 129 (1990). 
109 Greenberg v. Miami Children’s Hosp. Research Inst. 264 F. Supp. 2d 1064, 1070 (2003). 
110 Greely, supra note 63at 754. 
111 45 C.F.R. § 46.116 (2011). 
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8. Right to Withdraw 
The right to withdrawal is a current basic element of informed consent.112 However, as 
discussed in Part IV, there are complications related to withdrawal when research involves a 
biospecimen. While some argue that subjects should be able to withdraw from general or specific 
types of research,113 there may be practical limitations to this right which should be fully 
explained to the potential research subjects. Similar to the concern raised in the Research 
Findings section, if a name or code is no longer associated with the biospecimen, there may not 
be a way to withdraw that specimen from the study. This should be fully explained to the subject. 
If the researcher prospectively collecting the biospecimen plans to remove names and codes, 
eliminating the possibility for identification, this should be explained to the subject and 
information about when a subject would no longer be able to withdraw because of this should be 
fully explained in the consent document. 
Explaining what the right to withdraw does not mean should also be included within the 
consent document, such as the ability to have the biospecimen returned or directed to another 
party as discussed in Part IV.  
9. Applicable State Laws 
A requirement should be included that states that any relevant state laws or requirements 
must be included as applicable.  For example, while Michigan’s law on informed consent for 
genetic tests excludes biomedical research conducted in compliance with the Common Rule114, 
other states may not have similar exclusions. Michigan also has additional informed consent 
                                                   
112 45 C.F.R. § 46.116(a)(8) (2011). 
113 Greely, supra note 63at 754-55. 
114 MI COMPILED LAWS  333.17020 (2000). 
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requirements if the research involves embryos.115 Because biospecimens may have additional 
state requirements in regards to informed consent, the provision should be included to remind 
both investigators and institutions that requirements in addition to the Common Rule may also 
govern the informed consent process. 
10. If a Subject Declines Future Research 
The ANPR proposes that the subject’s decision for general research should have no bearing 
on the participation in the current research.116 Such a statement should be included in the consent 
document to fully explain to the subject that future research participation is optional and not 
required to participate in the prospectively proposed research study. If a subject declines to 
participate in future research that the biospecimen cannot be used in the future research without 
permission. If additional projects are proposed, the subject should be approached to obtain 
informed consent for the particular project. At the time the new project is proposed, the subject 
could again be presented with the option for general research and he or she may choose to now 
allow the biospecimen to be used for general research. However, the subjects’ wishes must 
govern and the informed consent process would need to conform to the prospective requirement 
to obtain informed consent for general research. 
B.  Duties 
In addition to informed consent provisions, there are additional approval criteria for research 
involving biospecimens that should be incorporated into the Common Rule to reflect the trust 
model.  The current regulation has specific approval criteria that must be satisfied to approve the 
                                                   
115 MICHIGAN CONSTITUTION OF 1963, § 27 Human Embryo and Embryonic Stem Cell Research (2008). 
116 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44520 (advanced notice of proposed rulemaking July 26, 2011) 
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research.117 An additional provision should be added that defines the duties of the researcher and 
the institution when reviewing biospecimens. A trust requires that beneficiaries and trustees have 
duties as part of the trust and a trust may fail for lack of duties.118 The following provisions 
should be incorporated into the Common Rule. 
1. Duties of the Researcher 
Investigator responsibilities for research involving biospecimens should be included in the 
Common Rule. This provision relates to his or her responsibility in the trust model as the 
“beneficiary” of the biospecimen.  
a. Storage and Recordkeeping 
While recordkeeping is required within the Common Rule, the investigator should be 
separately responsible for having in place a process to store and track biospecimens collected 
prospectively and to distinguish biospecimens for which subjects have provided consent for 
future research from biospecimens for which subjects have declined consent for future research.  
A description of the process should be provided to the institution for evaluation as part of the 
prospective review process. Because institutions may not have central biorepositories, the 
biospecimens may be stored and kept by the investigator. Additional information should be 
provided to assure proper storage and cataloging of which biospecimens could be eligible for 
future research and which would not. Best practices could be developed or required by the 
institution. Such best practices could be modeled on existing biorepository standards and could 
be promulgated as guidance by OHRP. Because the investigator will be in possession of the 
                                                   
117 45 C.F.R. § 46.111 (2011). 
118 RESTATEMENT (THIRD) OF TRUSTS § 13 (2003). 
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biospecimen, they have a responsibility as the beneficiary to assure that the biospecimen is 
stored and used as agreed upon in the informed consent document.  
b. Submission for Future Research 
Each future research use must be submitted to the institution so that the scope of the 
informed consent can be compared to the actual proposed use.  The investigator should 
understand that the research is limited to what has been approved by the IRB and that future 
research needs to be submitted to the IRB for review prior to use.  
2. Duties of the Institution 
Institution responsibilities for research involving biospecimens should be included in the 
Common Rule. This provision relates to his or her responsibility in the trust model as the 
“trustee” of the biospecimen.  
a. Approval and Monitoring 
Corresponding to the investigator’s responsibility for storage and tracking, the institution 
should be responsible for evaluating and approving the plan as part of the prospective review 
process. Modeled on a trustee, the institution has responsibility for assuring that the biospecimen 
is being used according to the informed consent document. This review should include not only 
the prospective review, but may also include monitoring of the approved research project. The 
monitoring would assure that the investigator is following the approved protocol for storage and 
tracking. 
b. Group Harms 
Concerns related to use of the biospecimens obtained from Havasupai tribe members 
included not only individual concerns about the research use, but cultural and group harms as 
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well.119 The Common Rule does not directly address cultural or group harms.120 The proposed 
changes would address the individual consent issues, but would not address cultural or group 
harms.121 It has been proposed that possible risks to the group should be disclosed through the 
informed consent process.122 This is a difficult area to address because defining the group and 
applicable standards may vary in context and may not be capable of simple definition. Native 
American groups could develop research codes that would require certain permissions before 
individual tribe members could participate in the research.123 The IRB could consider whether to 
require the researcher to obtain consent from the group,124 whether the researcher should consult 
with the tribe in the development of the research,125 or consider cultural and spiritual harms as 
part of the review process when research involves Native Americans.126 This is also difficult to 
address because the principle of respect for person centers on an individual’s autonomy to decide 
whether to participate in the research.127 However, for certain types of research, particularly 
involving Native tribes, a focus of the research is related specifically to the group.128 To better 
                                                   
119 Havasupai v. Ariz. State Univ., 220 Ariz. 214, 226 (2009). 
120 See 45 C.F.R. § 46.111 (2011) (does not include group harms). 
121 See Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512 (advanced notice of proposed rulemaking July 26, 2011) (does not 
specifically address cultural or group) 
122 E.g., Greely, supra note 63at 755, Richard Sharp, An Analysis of Research Guidelines on the Collection and Use of Human 
Biological Materials From American Indian and Alaskan Native Communities, 42 JURIMETRICS J. 165 (2002). 
123 E.g., Debra Harry, Indigenous Peoples and Gene Disputes, 84 CHI. KENT L. REV. 147 (2009), Ron J. Whitener, Research in 
Native American Communities in the Genetics Age: Can the Federal Data Sharing Statute of General Applicability and 
Tribal Control of Research be Reconciled? 15 J. TECH. L. & POL’Y 217 (2010) (Native American tribal codes should 
specifically address research and permission requirements). 
124 Greely, supra note 63at 756-57. 
125 E.g., Harry, supra note 123 at 193-97, Sharp, supra note 122.  
126 Katherine Drabiak-Syed, Lessons from Havasupai Tribe v. Arizona State University Board of Regents: Recognizing Group, 
Cultural, and Dignitary Harms as Legitimate Risks Warranting Integration into Research Practice, 6 J. HEALTH & 
BIOMEDICAL L. 175, 215-16 (2010) (factor cultural and spiritual harms when reviewing research that involves Native 
American biospecimens). 
127 E.g., 45 C.F.R. § 46 (2011) (principles embodied in regulations).  
128 E.g. Havasupai v. Ariz. State Univ., 220 Ariz. 214 (2009). 
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define this area, OHRP should obtain comments on how such criteria could be used and develop 
guidance that could then be published and used by institutions reviewing such research. 
III. RESEARCH INVOLVING EXISTING BIOSPECIMENS 
This part highlights the deficiencies in the Common Rule as applied to research involving 
existing biospecimens, compares the ANPR, and argues that additional changes as part of a trust 
model are needed to better protect subjects, investigators, and institutions. Part A discusses 
provisions related to when review by the institution should be required for existing biospecimens 
in research. Part B discusses considerations that the institution should take into account as part of 
the trust model for review of the proposed research involving an existing biospecimen.  
A.  Common Rule Applicability 
This part discusses when the Common Rule is applicable under the current requirements and 
the advance notice proposal, highlighting the deficiencies and proposing a trust model.  
1. Definition of a Human Subject 
A human subject is defined under the Common Rule as a living individual about whom an 
investigator . . . conducting research obtains data through intervention or interaction with the 
individual, or [i]dentifiable private information.129 Identifiable means the identity of the subject 
is or may be readily ascertained by the investigator or associated with the information.130 In the 
case of the blood obtained from the Havasupai tribe members, if the ASU investigator de-
identified the biospecimen, i.e. removed names or other identifiers and did not maintain or have 
access to codes linking an identifier to the subject,131 the blood sample obtained from the 
                                                   
129 45 C.F.R. § 46.102(f) (2011). 
130 45 C.F.R. § 46.102(f) (2011). 
131 OHRP Guidance on Research Involving Coded Private Information or Biological Specimens, 
http://www.hhs.gov/ohrp/policy/cdebiol.html (May 8, 2012). 
Kristen	  M.	  Burt	   Research	  Involving	  Biospecimens	   27	  
 
Havasupai tribe members may not have been considered a “human subject” under the Common 
Rule and would not have required IRB review, approval, or informed consent for the use of the 
blood sample by ASU in the research. The current definition of human subject as it relates to 
biospecimens excludes a significant amount of secondary research involving biospecimens and 
highlights a flaw in the current regulation.  A biospecimen holds an individual’s genetic make-up 
and can potentially identify a subject and it has been argued that biological materials should be 
considered identifiable based on the DNA.132 However, DNA alone is not considered 
“identifiable” under the Common Rule.133 
 To address this concern, the ANPR proposes that because DNA could be extracted from a 
biospecimen and used to link to other data to identify an individual, regardless of how the 
biospecimen is coded or de-identified, it is identifiable in and of itself.134 Because of this 
characteristic, biospecimens would be considered identifiable under the proposed changes.135 
While use of biospecimens in research, regardless of whether a name or code is 
maintained, should be reviewed by the institution as part of the trust model, distinctions should 
be maintained in terms of identification.  While all research use involving biospecimens should 
be reviewed under the Common Rule because of the unique characteristics of biospecimens, 
there should be a tiered approach when evaluating the usage of the biospecimen. The first tier of 
identification would be those specimens that are identifiable or readily identifiable to an 
individual person. This tier would include biospecimens that are associated with a name or code. 
The second tier of identification would be those specimens who cannot be tied directly to an 
                                                   
132 E.g., Wolf, supra note 64 at 147-48, Burger, supra note 84 at 76-80 (2009). 
133 45 C.F.R. § 46.102(f) (2011). (interpretation has not included DNA) 
134 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44525 (advanced notice of proposed rulemaking July 26, 2011) 
135 Id. 
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individual, i.e. no name or code. The rationale for this distinction is linked to the ability to 
withdraw from a research study. The ability to withdraw is discussed in Part IV and will 
highlight the need for this distinction. 
A potential issue that may arise if considering all biospecimens identifiable under the 
Common Rule is whether the individual is living which is a criterion to be considered a human 
subject.136 It is possible that biospecimens may be stored for many years and it may be difficult 
to determine if an individual is still living. Therefore, for research involving biospecimens, 
several options could be adopted. First, the year of birth could be obtained and maintained with 
the biospecimen and there could be a presumption that based on the age the individual is no 
longer living (e.g. 100) unless actual information is obtained to determine the individual is 
deceased. A second option, if researchers did not want to obtain year of birth, would be that the 
year of collection would be maintained and years would be added to that date for a determination 
if the individual is living (e.g. 100 years). This could be much longer than the first option, but 
could be used in cases where researchers did not want to collect year of birth.  
The Common Rule is applicable to private identifiable information.137 Another consideration 
related to the definition of human subject is what is considered private. Any collection of the 
biospecimen (either through research or clinical care) should be considered private. However, 
obtaining a commercial cell line would not be considered private as it is commercially available. 
However, consideration should be given to how commercial cell lines are developed to assure 
that concerns related to use of biospecimens in research are addressed. 
                                                   
136 45 C.F.R. § 46.102(f) (2011). 
137 45 C.F.R. § 46.102(f) (2011). 
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2. Exemption 4 
Even if the blood samples from the Havasupai tribe members originally fell under the 
Common Rule, the ASU investigators could have qualified for an exemption if the sample was 
de-identified.138   The Common Rule provides six exemptions, including Category 4 that 
specifically exempts research involving collection or study of existing materials, including 
biospecimens, so long as the subjects cannot be identified.139 This category could apply to 
biospecimens collected for research or it could apply to biospecimens collected for clinical 
purposes, so long as the biospecimens were existing at the time the research is proposed.140 
Because the research use is exempt from the Common Rule, informed consent is not required 
and it may have never been obtained for this particular research use (e.g. while Havasupai tribe 
members consented to diabetes research, they did not consent to research involving 
schizophrenia141).Typically, the institution’s IRB reviews the research to determine if the 
proposed research meets the exempt category.142 
 The ANPR proposed to expands the exemption category 4 to all secondary research use 
of identifiable data and biospecimens collected for purposes other than the currently proposed 
research, no matter when it is collected but requires written general consent for use of the 
biospecimen in research.143 While this initially sounds like it would address the concerns raised 
                                                   
138 45 C.F.R. § 46.101(b)(4) (2011). 
139 45 C.F.R. § 46.102(b)(4) (2011) (research involving the collection or study of existing data, documents, records, pathological 
specimens, or diagnostic specimens, if these sources are publicly available or if the information is recorded by the 
investigator in such a manner that subjects cannot be identified, directly or through identifiers linked to the subject). 
140 45 C.F.R. § 46.101(b)(4) (2011). 
141 Havasupai v. Ariz. State Univ., 220 Ariz. 214, 226 (2009). 
142 E.g., Michigan State University Human Research Protection Program Manual Section 8-1, 
http://www.humanresearch.msu.edu/hrpmanual.html (May 8, 2012) (sample institutional policy on exempt review).  
143 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011) 
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by the Havasupai tribe members144, there are potential flaws to this proposed change.  Rather 
than review by the institution or the IRB office, researchers would file a registration with the 
IRB and would then be allowed to proceed without IRB review with IRB review not being 
required or recommended.145 Instead, auditing by the institution of the ongoing studies would be 
relied upon to assure that the exempt criteria had been met.146 
 A trust model would better protect the interests of the subject, institution, and investigator 
with prospective submission by the investigator to the institution for review prior to research use 
of the existing biospecimen. For example, a researcher may mistakenly believe that the research 
qualifies for the exemption or does not realize the scope of the informed consent does not 
encompass the proposed research.  This could be especially problematic if the use of categories 
to exclude certain types of research from the future use is permitted.147 Requiring the institution, 
through the IRB, to review the proposed use to assure that the informed consent originally 
provided encompasses the proposed research provides a check and balance and operates within 
the trust model. The institution, as the trustee, has a responsibility to assure that the biospecimen 
is being used within the scope of informed consent.   
B.  Responsibilities 
In the trust model proposed, the investigator would be required to submit a request for the 
secondary research to the institution for review. The investigator should be required to comply 
with the investigator responsibilities outlined in Part II.  For example, investigators should 
describe where the biospecimen will be stored. The institution should also be required to comply 
                                                   
144 Havasupai v. Ariz. State Univ., 220 Ariz. 214, 226 (2009). 
145 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011) 
146 Id. 
147 Id. at 44519-20. 
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with the institution responsibilities in Part II. For example, it has been argued that subsequent 
research that involves potentially sensitive topics, such as stigmas, should be taken into 
consideration when reviewing the secondary research request by the IRB.148 The discussion 
related to cultural or group harms would also be applicable to secondary research use. 
In  addition to the responsibilities discussed in Part II, the institution should also be 
responsible for reviewing the scope of the original informed consent against the proposed 
research project involving existing biospecimens. This is the main consideration of whether the 
research can proceed using the existing biospecimens; the proposed research must meet the 
scope of original consent document. Because the original informed consent document would be 
considered the terms of the trust, the document provides the boundaries of the types of research 
the human subject agreed to when signing the original document. This evaluation by the 
institution will be particularly important if the controversial categories of research that subjects 
can opt out of participating in are included in the informed consent document.149 The IRB would 
review the proposed research project with the consent forms presented to the subject. If multiple 
consent forms were reviewed and approved by the IRB (e.g. revisions to the document), each 
consent document would be reviewed by the IRB. The IRB should assure that the research 
proposed is consistent to what the human subject agreed to within the informed consent. 
IV. WITHDRAWAL AND SHARING 
This section will evaluate withdrawal and sharing of the biospecimen after the research is 
approved and argue that the trust model provides a better structure to address these areas. Part A 
describes withdrawal procedures if a subject who provided informed consent requests 
                                                   
148 Greely, supra note 63 at 752-54. 
149 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519-20 (advanced notice of proposed rulemaking July 26, 2011) 
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withdrawal and this paper argues that the right to withdraw would be facilitated by using a trust 
based model. Part B describes the sharing of the biospecimen and argues that if the biospecimen 
is going to shared outside the institution, such use should also be reviewed by the institution to 
assure the use conforms to the subjects’ wishes.  
A.  Withdrawal 
The right of an individual participating in research to withdraw at any time for any reason is 
an essential component of the human research protection regulations.150 However, if the research 
did not include a human subject or was exempt, the option to withdraw was not presented to the 
individual, who may not even know what research projects the biospecimen is being used in.151 
The right to withdraw typically was presented to subjects during the informed consent process to 
obtain the biospecimen, 152 but after the biospecimen became de-identified, that ability to 
withdraw was lost.  
With the ANPR, the general consent option addresses the issue of obtaining consent for all 
research involving the biospecimen.153 However, the ANPR did not indicate how the right to stop 
participating would be incorporated into the Common Rule.154 Because all specimens are 
considered identifiable under the ANPR, it would logically follow that individuals could 
withdraw their permission and allow the specimen to stop being used at any time. However, this 
practically would not be possible unless a name or code was associated with the biospecimen. If 
the biospecimen has become de-identified with no name or code associated with the specimen, 
                                                   
150 45 C.F.R. § 46.116(a)(8) (2011). 
151 45 C.F.R. § 46.101 (2011) (applicability of Common Rule) 
152 45 C.F.R. § 46.116(a)(8) (2011). 
153 Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512, 44519 (advanced notice of proposed rulemaking July 26, 2011) 
154 See Human Subjects Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and 
Ambiguity for Investigators, 76 Fed. Reg. 44512 (advanced notice of proposed rulemaking July 26, 2011) (does not include 
withdrawal procedures for biospecimens) 
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there is no way for a researcher to be able to remove that biospecimen from all the biospecimens 
being analyzed.155  It has been argued that names should be unlinked from the biospecimen or 
strongly coded.156 For example, the study may be on a very sensitive topic that an individual may 
not want their name associated with, such as perhaps a study involving use of illegal drugs, 
sexually transmitted diseases, etc. Strong confidentiality protections are necessary, but requiring 
unlinking may eliminate the ability to withdraw.  
If biospecimens are considered identifiable in two tiers as discussed in Part II, withdrawal in 
the first tier of identification where there is a name or code link to a name could be accomplished 
since there would be a way to link the request to a biospecimen. In the second tier where there is 
no code, there are several options. One option is to fully explain in the consent process what this 
type identification means and at what point subjects would no longer be able to withdraw. 
Another option would be to code the specimens in such a way where a number is provided to the 
subject and linked to the specimen, but no record is kept on who has what number. This could 
maintain the ability to remove name or other explicit identifiers but still allow the subjects to 
withdraw their biospecimens from research. 
Because the right of withdrawal might impact multiple studies, a prerequisite to research use 
of existing biospecimens is the understanding that if a subject requests withdrawal, this 
withdrawal would extend to all ongoing research use. The trust model can facilitate the right to 
withdraw because at the institutional level, the original research project could be linked to all 
research projects involving existing biospecimens. The institution could then contact each 
individual researcher and provide information about the subject request for withdrawal. A 
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156 Greely, supra note 63 at 756.  
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prerequisite to participating in research involving existing biospecimens would be the 
understanding that request for subject withdrawal would need to be reported to the institution so 
that it may be shared for all research projects using the biospecimen.  
B.  Sharing 
In the case of Washington v. Catalona, biospecimens were collected by a researcher for many 
years and stored at a biorepository at Washington University.157 The researcher accepted a 
position at Northwestern and sought to have the samples transferred.158 To do this, the researcher 
contacted the subjects to obtain their permission to transfer the samples.159 However, 
Washington University filed for a declaratory judgment to establish ownership of the 
biospecimens.160 The court determined that under the facts of this case, individuals who make an 
informed decision to contribute their biological material voluntarily to a research institute for the 
purpose of medical research do not retain an ownership interest allowing the individuals to direct 
or authorize the transfer of such materials to a third party.161 The analysis of the court focused on 
the informed consent documents and Material Transfer Agreements.162 Material Transfer 
Agreements are executed when materials are being exchanged with another institution to protect 
intellectual property rights.163 The court’s analysis focused on ownership of the particular 
specimen under gift law164, which has been a heavily debated topic165 which is beyond the scope 
                                                   
157 Wash. Univ. v. Catalona, 490 F.3d 667, 670 (2007). 
158 Id. at 672. 
159 Id. 
160 Id. 
161 Id. at 673. 
162 Id. at 674-76. 
163 http://ttc.nci.nih.gov/forms/ (May 8, 2012) (U.S. National Cancer Institute forms page that include the Uniform Biological 
Material Transfer Agreement). 
164 Wash. Univ. v. Catalona, 490 F.3d 667, 676 (2007). 
165 See e.g., William Hanes, Rejection of the Need for Informed Consent in Prostate Tissue Sample Research, 14 CARDOZO J.L. & 
GENDER 401, (donation may be a bailment, not a gift), Donna Gitter, Ownership of Human Tissue: A Proposal for Federal 
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of this paper. However, the examination of the language of the informed consent document and 
Material Transfer Agreements is relevant because it is used to determine what the institution, 
subject, and investigator understood about the research arrangement.  
As part of the trust, the institution should have the office that executes Material Transfer 
Agreements obtain approval or sign off by the institution through the IRB before an MTA was 
executed. The approval or sign off would be required to assure that the scope of the informed 
consent allows the specimen to be transferred to the other party for the purposes of the research 
being requested. The MTA, in addition to intellectual property provisions, should also 
incorporate limiting provisions in terms of how the biospecimen can be used, transferred, and 
withdrawal provisions. These terms should be congruent with the scope of the original informed 
consent. If such terms were not included and the specimen was released, it would essentially 
negate the trust model and allow the collaborating institution to use the specimen in such a way 
that would not have been permitted by the institution’s own employees.  
The court in Catalona also determined that the subjects did retain the right to revoke and 
physically possess the materials and did not retain the right to direct or authorize the use, 
transfer, or destination of the biological materials after donation based on biohazard laws.166 The 
court in Moore came to a similar conclusion applying California biohazard laws.167  While there 
is a delicate balance regarding exculpatory language, subjects should know prior to taking part in 
the research that the biospecimen won’t be able to be returned. In addition, use of the term 
                                                                                                                                                                    
Recognition of Human Research Participants’ Property Rights in Their Biological Materials, 61 WASH. & LEE L. REV. 257 
(2004) (create federal law that establishes individual property rights in tissue and would have a cause of action for 
conversion under certain circumstances), Kimberly Self, Self-Interested: Protecting the Cultural and Religious Privacy of 
Native Americans Through The Promotion of Property Rights in Biological Materials, 35 AM. INDIAN L. REV. 729 (2010), 
Russell Korobkin, No Compensation or Pro Compensatio: Moore v. Regents and Default Rules for Human Tissue 
Donations, 40 J. HEALTH L 1 (2007).. 
166 Wash. Univ. v. Catalona, 490 F.3d 667, 675 (2007). 
167 Moore v. Regents Univ.  Cal., 51 Cal.3d 120, 155-56 (1990). 
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“donation” has been seen as exculpatory.168 Realizing some of the use of terminology is related 
to ownership issues which are beyond the scope of this paper, it may be appropriate to solicit 
comments to develop and provide guidance on this particular topic to assure that language used 
by institutions is not exculpatory, recognizing some of this will be dependent upon state laws. 
CONCLUSION 
Research involving biospecimens will likely continue to grow as advances are made in 
medicine and technology. For example, the U.S National Institute of Health is focusing on 
repurposing existing molecular compounds169 and is working on developing 3-D tissue chips that 
can be used to test the molecular compounds for toxicity and binding on the targets as part of 
new drug development.170 These chips would contain human tissue and be microsystems used to 
eliminate ineffective molecules.171  As research involving existing biospecimens continues to 
grow, the Common Rule must adapt to balance both the researchers’ need for access to 
biospecimens for research and the expectations of the individuals who provide their biological 
materials that are then used in research. The process must be designed to both respect the human 
subject who participates in the research while also permitting research to occur without unduly 
burdensome requirements.   
At this point in the rulemaking process, the ANPR suggested potential changes and 
presented questions for input.172 While the comment period for the ANPR has closed173, the next 
step in the rulemaking process will be a proposed rule that under the Fall 2011 Unified Agenda 
                                                   
168 Burger, supra note 84 at 69. 
169 http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/therapeutic-uses.html (May 9, 2012) 
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had been anticipated, but not yet published, for March 2012.174 Opportunity for providing 
comments will still be possible.   
While the ANPR partially addresses deficiencies in the Common Rule raised by 
litigation,175 additional modifications to the Common Rule are needed to protect the interests of 
the human subject participating in the research, investigators conducting the research, and the 
institution supporting the research. As this paper has argued, a model based on a trust structure 
appropriately balances each of the competing interests of the parties. Subjects can decide to 
provide informed consent for future general research involving their biospecimen. Investigators 
are able to conduct the future research without having to re-consent each subject for each 
individual project. The institution provides a check on this process by requiring review of the 
research on the existing biospecimen to assure that the scope of the consent covers the proposed 
research use. The model balances each interest while not making the process so overly 
burdensome that the research could not practicably be carried out.  
* * * 
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